News | April 07, 2022
Indian pharma growth likely to moderate in FY23: ICRA
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
An integrated and agile approach enables the pharmaceutical CDMO industry to simplify manufacturing as it moves from primary care medicines to specialty medicines
MilliporeSigma to become the first company to offer a fully integrated ecosystem for advanced process technologies
The partnership demonstrates increasing adoption of tetra data to create unrestricted innovation
The new facility is scheduled to start operation in the first half of 2024
Casper Pharma is a Hyderabad based SEZ company engaged in the formulations business. Post-purchase of shares, the target entity would become a wholly-owned subsidiary of SPL
New simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of innovation, growth and productivity
Sanofi’s DE&I Board will include three of the most influential voices in the DE&I space as Board members appointed for 3 years: organizational psychologist & best-selling author John Amaechi, award-winning social entrepreneur Caroline Casey, and DE&I pioneer and renowned thought-leader Dr. Rohini Anand
It aims to make the state-of-the-art modern and safe surgical care, typically available in super-speciality hospitals of big cities, accessible, affordable, standardized and integrated
The investment will significantly enhance the development of high-purity lipid systems, essential delivery systems for next generation nucleic acid drugs such as mRNA vaccines
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
